ReviewCellular and molecular life sciences : CMLS2023
Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
Review in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Lipid profile alterations in pulmonary tuberculosis patients with and without diabetes mellitus: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Mce transport systems inJournal of bacteriology · 2026Review
- Integrating Untargeted Metabolomics and Transcriptomics in Mice with Pulmonary Tuberculosis to Reveal Changes in Linoleic Acid and Its Metabolism in Lung Monocyte-Derived Macrophages.Pathogens (Basel, Switzerland) · 2026Article
- Exploring the Protein Landscape of Dormant Mycobacterium tuberculosis Through In Vitro Functional Studies.Advances in experimental medicine and biology · 2026Review
- Metabolic reprogramming of macrophages during mycobacterial infection: a review of immunometabolic crosstalk and pathogen manipulation.Frontiers in cellular and infection microbiology · 2026Review
- Lipid profiling in nontuberculous mycobacterial pulmonary disease based on geospatial locations and disease severity.ERJ open research · 2026Article
- Untargeted and Targeted Liquid Chromatography-Mass Spectrometry-Based Lipidomic Profiling Revealed a Potential Biomarker Panel to Distinguish Clinical Isolates of M. tuberculosis From Nontuberculous M. kansasii.Pulmonary medicine · 2026Article
- Comparative in silico analysis of mce operons across Mycobacteriaceae and Nocardiaceae: Insights into genetic arrangements and regulatory mechanisms.Archives of microbiology · 2025Article
- Dormant yet dangerous: the role of cell rest in perseverance.Future microbiology · 2025Review
- Kupyaphores─Self-Assembling Diisocyanolipopeptide ZnJournal of the American Chemical Society · 2025Article
- A predictive model for evaluating the risk of latent tuberculosis relapse via machine learning.BMC infectious diseases · 2025Article
- Trimming the fat: a brief review of lipids at the host-pathogen interface.Infection and immunity · 2025Review
- Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates ofeLife · 2025Article
- Development and Validation of Early Alert Model for Diabetes Mellitus-Tuberculosis Comorbidity.Microorganisms · 2025Article
- Mendelian randomization study of lipid species reveals causal relationship with syphilis.AMB Express · 2025Article
- Feature selection and aggregation for antibiotic resistance GWAS inFrontiers in microbiology · 2025Article
- Article
- Contribution of infectious diseases to the selection of ADH1B and ALDH2 gene variants in Asian populations.Alcohol, clinical & experimental research · 2024Article
- Fluvastatin Converts Human Macrophages into Foam Cells with Increased Inflammatory Response to InactivatedCells · 2024Article
- From pathogenesis to antigens: the key to shaping the future of TB vaccines.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lipid species play a critical role in the growth and virulence expression of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). During Mtb infection, foamy macrophages accumulate lipids in granulomas, providing metabolic adaptation and survival strategies for Mtb against multiple stresses. Host-derived lipid species, including triacylglycerol and cholesterol, can also contribute to the development of drug-tolerant Mtb, leading to reduced efficacy of antibiotics targeting the bacterial cell wall or transcription. Transcriptional and metabolic analyses indicate that lipid metabolism-associated factors of Mtb are highly regulated by antibiotics and ultimately affect treatment outcomes. Despite the well-known association between major antibiotics and lipid metabolites in TB treatment, a comprehensive understanding of how altered lipid metabolites in both host and Mtb influence treatment outcomes in a drug-specific manner is necessary to overcome drug tolerance. The current review explores the controversies and correlations between lipids and drug efficacy in various Mtb infection models and proposes novel approaches to enhance the efficacy of anti-TB drugs. Moreover, the review provides insights into the efficacious control of Mtb infection by elucidating the impact of lipids on drug efficacy. This review aims to improve the effectiveness of current anti-TB drugs and facilitate the development of innovative therapeutic strategies against Mtb infection by making reverse use of Mtb-favoring lipid species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.